HOME >> BIOLOGY >> NEWS
Where's Waldo's DNA? New NIST SRM joins search

A new reference standard from the National Institute of Standards and Technology (NIST) may help genetics labs develop improved methods of searching for a mutant needle in a DNA haystack.

A single DNA molecule carrying part of a person's genetic code is a chain of basic chemical units called nucleotides. The number of nucleotides can range from about 16,500 in mitochondrial DNA (mtDNA) to several million in nuclear DNA. A key mutation in a DNA strand may involve only a single nucleotide and yet cause serious health effects.

Accurate analysis of mitochondrial DNA (mtDNA), either for forensic identification or for studying genetic-based diseases, often hinges on the ability to detect such mutations that occur only infrequently, even in the same individual. Unlike the cell's nuclear DNA, a person's mtDNA is often heteroplasmic--a mix of a dominant DNA sequence with fewer mutated sequences that differ from the dominant version by one or more nucleotides. There are hundreds or thousands of mitochondria in cells, and the exact percentage of the minority mtDNA in the mix can vary dramatically in an individual from tissue to tissue and even from cell to cell. In general, it can be very difficult to identify variants that make up less than 20 percent of the sample unless you already know they are there.

Researchers face a similar problem of detecting low-frequency variants when analyzing pooled samples of nuclear DNA from a population of individuals in the hope of identifying specific mutations responsible for genetic diseases.

To help the research community develop and test more sensitive techniques for detecting low-frequency mutations in heteroplasmic DNA, NIST researchers have developed a new Standard Reference Material, SRM 2394, "Heteroplasmic Mitochondrial DNA Mutation Detection Standard." The new material is a set of mixtures, at 10 different certified concentrations, of two DNA fragments that differ from each other at only one positio
'"/>

Contact: Michael Baum
michael.baum@nist.gov
301-975-2763
National Institute of Standards and Technology (NIST)
24-Mar-2005


Page: 1 2

Related biology news :

1. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
2. International Astronautical Federation joins project to protect World Heritage sites
3. T-beta-RIII joins the fight against breast cancer
4. ESA joins UN climate talks in Kenya
5. Wildlife Conservation Society joins Climate, Community & Biodiversity Alliance
6. Springer joins Katrina relief effort with eBooks donation worth more than $1 million
7. Jackson Laboratory joins National Centers for Systems Biology
8. History of Earth Sciences Society joins AGI
9. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
10. Saudi Arabias KAUST names WHOI first research partner
11. Multinational research: protecting ecology means understanding people, too

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Where Waldo DNA New NIST SRM joins search

(Date:5/21/2013)... researchers have developed a new method for delivering ... in the cell surface. The technique could find ... biological fields. , Bulk electroporation a technique ... nanopores in the cell membrane that are caused ... an increasingly popular method of cell transfection. (Cell ...
(Date:5/21/2013)... keeping in shape is an uphill battle? Try staying ... prolonged weightlessness withers muscle and bone. , That,s the ... address with a new three-year, $1.2 million grant from ... exercise during multiyear exploratory missions. , "You could give ... you can,t get them to stick to it, it ...
(Date:5/21/2013)... 2013 Royal Philips Electronics (NYSE: PHG, AEX: ... portable ultrasound with Philips, industry leading Live 3D TEE, ... xMATRIX with available Live 3D TEE and ICE will ... the EuroPCR, official meeting for the European Association of ... its launch in 2012, Philips CX50 xMATRIX has been ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
(Date:5/22/2013)... 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced ... Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer of Cleveland ... May 30 at 1:30 p.m. Eastern Time.  A live and ... the Investors page of the Cleveland BioLabs website at ...
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) ... are pleased to announce a sponsorship agreement with Erebus ... Zealand distributor of DrugCheck® onsite testing devices, manufactured by ... the Austin 400 May 17-19 in Austin, Texas. , ... involves each car of the Erebus Motorsport team displaying ...
(Date:5/22/2013)... A recent study from researchers in Tasmania ... that those who took probiotics were able to run for ... showed that in extreme heat conditions, probiotics were able to ... acne treatment explains what this new discovery means for ... skin condition. , While researchers tote the benefits of ...
(Date:5/21/2013)... First patients dosed with PSX1002, ... designed using Prosonix, particle engineering platform Prosonix, ... inhaled Respiratory Medicines by Design , has initiated ... assess its effect on lung function and the safety ... to severe chronic obstructive pulmonary disease (COPD). The first ...
Breaking Biology Technology:Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
Cached News: